Non-steroidal anti-inflammatory drugs (NSAIDs), pain and aging: Adjusting prescription to patient features

Detalhes bibliográficos
Autor(a) principal: Ribeiro, Hugo
Data de Publicação: 2022
Outros Autores: Rodrigues, Inês, Napoleão, Leonardo, Lira, Luís, Marques, Denise, Veríssimo, Manuel T., Andrade, José Paulo, Dourado, Marília
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: http://hdl.handle.net/10316/100491
https://doi.org/10.1016/j.biopha.2022.112958
Resumo: A narrative review of papers published from January 2011 to December 2021, after a literature search in selected databases using the terms "pharmacokinetics", "ibuprofen", "diclofenac", "acemetacin", "naproxen", "etodolac" and "etoricoxib" was performed. From 828 articles identified, only eight met the inclusion criteria. Selective COX-2 inhibitors are associated with higher cardiovascular risk, while non-selective COX inhibitors are associated with higher gastrointestinal risk. NSAIDs with lower renal excretion with phase 2 metabolism are less likely to induce adverse effects and drug-drug interactions. Patients with frequent NSAID use needs, such as elderly patients and patients with cardiovascular disease or impaired renal function, will benefit from lower renal excretion (e.g. acemethacin, diclofenac, and etodolac) (level of evidence 3). Polymedicated patients, elderly patients, and patients with chronic alcohol abuse will be at a lower risk for adverse effects with NSAIDs that undergo phase 2 liver biotransformation, namely, acemethacin and diclofenac (level of evidence 3). Young patients, patients dealing with acute pain, or with active and/or chronic symptomatic gastritis, selective COX-2 inhibitors (celecoxib or etoricoxib) may be a better option (level of evidence 2). Knowing the individual characteristics of the patients, combined with knowledge on basic pharmacology, offers greater safety and better adherence to therapy. PERSPECTIVE: Although there are several NSAIDs options to treat pain, physicians usually take special care to its prescription regarding cardiovascular and gastrointestinal side effects, despite the age of the patient. In this paper, based on the best evidence, the authors present a review of the safest NSAIDs to use in the elderly.
id RCAP_f6609aae662bc64e7f9ad01df6d68574
oai_identifier_str oai:estudogeral.uc.pt:10316/100491
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling Non-steroidal anti-inflammatory drugs (NSAIDs), pain and aging: Adjusting prescription to patient featuresAnti-inflammatory drugsNarrative reviewPainPharmacokineticsA narrative review of papers published from January 2011 to December 2021, after a literature search in selected databases using the terms "pharmacokinetics", "ibuprofen", "diclofenac", "acemetacin", "naproxen", "etodolac" and "etoricoxib" was performed. From 828 articles identified, only eight met the inclusion criteria. Selective COX-2 inhibitors are associated with higher cardiovascular risk, while non-selective COX inhibitors are associated with higher gastrointestinal risk. NSAIDs with lower renal excretion with phase 2 metabolism are less likely to induce adverse effects and drug-drug interactions. Patients with frequent NSAID use needs, such as elderly patients and patients with cardiovascular disease or impaired renal function, will benefit from lower renal excretion (e.g. acemethacin, diclofenac, and etodolac) (level of evidence 3). Polymedicated patients, elderly patients, and patients with chronic alcohol abuse will be at a lower risk for adverse effects with NSAIDs that undergo phase 2 liver biotransformation, namely, acemethacin and diclofenac (level of evidence 3). Young patients, patients dealing with acute pain, or with active and/or chronic symptomatic gastritis, selective COX-2 inhibitors (celecoxib or etoricoxib) may be a better option (level of evidence 2). Knowing the individual characteristics of the patients, combined with knowledge on basic pharmacology, offers greater safety and better adherence to therapy. PERSPECTIVE: Although there are several NSAIDs options to treat pain, physicians usually take special care to its prescription regarding cardiovascular and gastrointestinal side effects, despite the age of the patient. In this paper, based on the best evidence, the authors present a review of the safest NSAIDs to use in the elderly.2022-06info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articlehttp://hdl.handle.net/10316/100491http://hdl.handle.net/10316/100491https://doi.org/10.1016/j.biopha.2022.112958eng07533322Ribeiro, HugoRodrigues, InêsNapoleão, LeonardoLira, LuísMarques, DeniseVeríssimo, Manuel T.Andrade, José PauloDourado, Maríliainfo:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2022-06-24T20:31:16Zoai:estudogeral.uc.pt:10316/100491Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T21:17:52.129169Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv Non-steroidal anti-inflammatory drugs (NSAIDs), pain and aging: Adjusting prescription to patient features
title Non-steroidal anti-inflammatory drugs (NSAIDs), pain and aging: Adjusting prescription to patient features
spellingShingle Non-steroidal anti-inflammatory drugs (NSAIDs), pain and aging: Adjusting prescription to patient features
Ribeiro, Hugo
Anti-inflammatory drugs
Narrative review
Pain
Pharmacokinetics
title_short Non-steroidal anti-inflammatory drugs (NSAIDs), pain and aging: Adjusting prescription to patient features
title_full Non-steroidal anti-inflammatory drugs (NSAIDs), pain and aging: Adjusting prescription to patient features
title_fullStr Non-steroidal anti-inflammatory drugs (NSAIDs), pain and aging: Adjusting prescription to patient features
title_full_unstemmed Non-steroidal anti-inflammatory drugs (NSAIDs), pain and aging: Adjusting prescription to patient features
title_sort Non-steroidal anti-inflammatory drugs (NSAIDs), pain and aging: Adjusting prescription to patient features
author Ribeiro, Hugo
author_facet Ribeiro, Hugo
Rodrigues, Inês
Napoleão, Leonardo
Lira, Luís
Marques, Denise
Veríssimo, Manuel T.
Andrade, José Paulo
Dourado, Marília
author_role author
author2 Rodrigues, Inês
Napoleão, Leonardo
Lira, Luís
Marques, Denise
Veríssimo, Manuel T.
Andrade, José Paulo
Dourado, Marília
author2_role author
author
author
author
author
author
author
dc.contributor.author.fl_str_mv Ribeiro, Hugo
Rodrigues, Inês
Napoleão, Leonardo
Lira, Luís
Marques, Denise
Veríssimo, Manuel T.
Andrade, José Paulo
Dourado, Marília
dc.subject.por.fl_str_mv Anti-inflammatory drugs
Narrative review
Pain
Pharmacokinetics
topic Anti-inflammatory drugs
Narrative review
Pain
Pharmacokinetics
description A narrative review of papers published from January 2011 to December 2021, after a literature search in selected databases using the terms "pharmacokinetics", "ibuprofen", "diclofenac", "acemetacin", "naproxen", "etodolac" and "etoricoxib" was performed. From 828 articles identified, only eight met the inclusion criteria. Selective COX-2 inhibitors are associated with higher cardiovascular risk, while non-selective COX inhibitors are associated with higher gastrointestinal risk. NSAIDs with lower renal excretion with phase 2 metabolism are less likely to induce adverse effects and drug-drug interactions. Patients with frequent NSAID use needs, such as elderly patients and patients with cardiovascular disease or impaired renal function, will benefit from lower renal excretion (e.g. acemethacin, diclofenac, and etodolac) (level of evidence 3). Polymedicated patients, elderly patients, and patients with chronic alcohol abuse will be at a lower risk for adverse effects with NSAIDs that undergo phase 2 liver biotransformation, namely, acemethacin and diclofenac (level of evidence 3). Young patients, patients dealing with acute pain, or with active and/or chronic symptomatic gastritis, selective COX-2 inhibitors (celecoxib or etoricoxib) may be a better option (level of evidence 2). Knowing the individual characteristics of the patients, combined with knowledge on basic pharmacology, offers greater safety and better adherence to therapy. PERSPECTIVE: Although there are several NSAIDs options to treat pain, physicians usually take special care to its prescription regarding cardiovascular and gastrointestinal side effects, despite the age of the patient. In this paper, based on the best evidence, the authors present a review of the safest NSAIDs to use in the elderly.
publishDate 2022
dc.date.none.fl_str_mv 2022-06
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10316/100491
http://hdl.handle.net/10316/100491
https://doi.org/10.1016/j.biopha.2022.112958
url http://hdl.handle.net/10316/100491
https://doi.org/10.1016/j.biopha.2022.112958
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 07533322
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.source.none.fl_str_mv reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799134074280869888